Microsoft buys Merck unit in life sciences push
Microsoft said on Monday it is buying the assets of Rosetta Biosoftware, a unit of Merck, as part of an effort to expand into the life sciences software arena.
The Rosetta technology will be used to add genetic and genomic data management abilities to Microsoft's recently announced Amalga Life Sciences effort.
As part of the deal, Merck will now become an Amalga customer, Microsoft said, Merck will also "provide strategic input to Microsoft on the direction and evolution of new solutions incorporating Rosetta Biosoftware technologies."
"This agreement establishes a stable and sustainable platform for the Rosetta … Read more